<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Birt-Hogg-Dubé syndrome
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Birt-Hogg-Dubé syndrome
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Birt-Hogg-Dubé syndrome
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Edward W Cowen, MD, MHSc
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jennifer L Hand, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Rosamaria Corona, MD, DSc
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Feb 08, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H25197012">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Birt-Hogg-Dubé syndrome (BHD; MIM #135150) is an autosomal dominant condition first described in 1977, characterized by benign skin hamartomas, most commonly located on the head and neck; pulmonary cysts and spontaneous pneumothorax; and an increased risk of renal cancer. BHD syndrome is caused by germline variants in the folliculin gene (
         <em>
          FLCN
         </em>
         ), which encodes the protein folliculin, a putative tumor suppressor gene whose function is still under investigation.
        </p>
        <p>
         This topic review will discuss the pathogenesis, clinical features, diagnosis, and management of BHD syndrome. Renal tumors and other inherited renal cancer syndromes are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2983.html" rel="external">
          "Clinical manifestations, evaluation, and staging of renal cell carcinoma"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2948.html" rel="external">
          "Hereditary kidney cancer syndromes"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H25197018">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The incidence of Birt-Hogg-Dubé (BHD) syndrome is unknown. Approximately 200 families have been identified worldwide [
         <a href="#rid1">
          1
         </a>
         ]. The overall penetrance of folliculin (
         <em>
          FLCN
         </em>
         ) variants in affected families is high; however, the presence of cutaneous, pulmonary, and renal manifestations varies significantly, even within families. Although the penetrance of renal cancer is relatively low, patients with BHD syndrome have a sevenfold increased risk of kidney tumors compared with the general population [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
         In a review of 89 patients with BHD syndrome from 51 families from the National Institutes of Health (NIH), cutaneous lesions were found in 90 percent of patients, pulmonary cysts in 84 percent, and history of pneumothorax in 38 percent [
         <a href="#rid3">
          3
         </a>
         ]. Renal tumors were found in 30 patients from 25 families, indicating that most families with renal tumors had only one member affected, even after screening all carriers of
         <em>
          FLCN
         </em>
         variants for renal tumors with abdominal computed tomography (CT) or magnetic resonance imaging (MRI) of the kidneys.
        </p>
        <p class="headingAnchor" id="H25197024">
         <span class="h1">
          PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Birt-Hogg-Dubé (BHD) syndrome is caused by germline autosomal dominant pathogenic variants in the folliculin (
         <em>
          FLCN
         </em>
         ) gene, located on chromosome 17p11.2. These variants include small insertion/deletions, splice-site, and nonsense variants, which lead, in most cases, to premature truncation and loss of function of the folliculin protein [
         <a href="#rid4">
          4
         </a>
         ]. Over 180 unique
         <em>
          FLCN
         </em>
         germline disease variants spanning all 14 exons have been identified in families with BHD syndrome and catalogued in the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.lovd.nl%2F3.0%2Fhome&amp;token=X6pqtZnY0%2FxnhfBU%2FZxbb3hfw%2F68SugtVvTTo0SiYPwXxTslbPTPLhI6QaQGB8ZF&amp;TOPIC_ID=100661" target="_blank">
          Leiden Open Variation Database (version 3.0)
         </a>
         .
        </p>
        <p>
         Although folliculin is thought to function as a tumor suppressor, its exact mechanism of action remains unknown [
         <a href="#rid5">
          5
         </a>
         ]. Loss of heterozygosity due to somatic "second hit" mutations has been demonstrated in 53 percent of BHD syndrome renal tumors [
         <a href="#rid6">
          6
         </a>
         ]. Protein-protein interaction studies led to the identification of folliculin-interacting proteins 1 and 2 (FNIP1 and FNIP2, respectively) [
         <a href="#rid7">
          7
         </a>
         ].
         <em>
          FLCN
         </em>
         and FNIP1 interact with 5'-AMP-activated protein kinase (AMPK), a negative regulator of mechanistic target of rapamycin (mTOR). This finding suggests that
         <em>
          FLCN
         </em>
         may act as a tumor suppressor by controlling the interactions between FNIP1/FNIP2 and the mTOR signaling pathway [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
         Studies on FNIP knockout mouse models support the hypothesis that these interacting proteins play a key role in kidney tumorigenesis [
         <a href="#rid8">
          8
         </a>
         ]. Loss of heterozygosity has not been detected in fibrofolliculomas, which demonstrate a strong expression of
         <em>
          FLCN
         </em>
         messenger ribonucleic acid (mRNA) [
         <a href="#rid9">
          9,10
         </a>
         ]. These findings suggest that haploinsufficiency of folliculin is sufficient to initiate the development of these skin tumors.
        </p>
        <p class="headingAnchor" id="H25197030">
         <span class="h1">
          CLINICAL MANIFESTATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The phenotype of Birt-Hogg-Dubé (BHD) syndrome is highly heterogeneous within families and between families sharing the same folliculin (
         <em>
          FLCN
         </em>
         ) variant. No clear correlations have been identified between the type of variant in
         <em>
          FLCN
         </em>
         and the extent of skin involvement and lung or kidney manifestations [
         <a href="#rid5">
          5
         </a>
         ]. Some patients may develop cutaneous lesions only; others may present with cutaneous lesions and pulmonary manifestations or cutaneous lesions and kidney tumors. In some patients, pulmonary cysts or renal tumors may be the only manifestation of the disease.
        </p>
        <p class="headingAnchor" id="H25197037">
         <span class="h2">
          Cutaneous lesions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Fibrofolliculomas are typically the earliest and most frequent manifestation of BHD syndrome. They begin to appear in the third decade of life in approximately 90 percent of patients and present as round, white-gray papules 1 to 4 mm in size, some of which show a dell in the center corresponding to the follicular opening. Lesions as large as 8 mm and cystic or comedonal lesions may also occur [
         <a href="#rid11">
          11
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/16910.html" rel="external">
          "Cutaneous adnexal tumors", section on 'Follicular tumors'
         </a>
         .)
        </p>
        <p>
         The midface (cheeks, nose) is most densely affected, and the papules are also often most prominent at this location  (
         <a class="graphic graphic_picture graphicRef106136" href="/z/d/graphic/106136.html" rel="external">
          picture 1
         </a>
         ), particularly in fair-skinned individuals with a rosaceiform complexion  (
         <a class="graphic graphic_picture graphicRef106138" href="/z/d/graphic/106138.html" rel="external">
          picture 2A
         </a>
         ). Lesions may develop anywhere on the head/neck, including the posterior ears  (
         <a class="graphic graphic_picture graphicRef106139" href="/z/d/graphic/106139.html" rel="external">
          picture 3
         </a>
         ). Isolated papules on the neck may be difficult to differentiate from acrochordons (skin tags) or small seborrheic keratoses  (
         <a class="graphic graphic_picture graphicRef106140" href="/z/d/graphic/106140.html" rel="external">
          picture 2B
         </a>
         ).
        </p>
        <p>
         Affected patients will continue to slowly accumulate new lesions and experience enlargement of pre-existing lesions throughout life. However, some patients have only a small number of lesions by late adulthood, whereas others may develop hundreds, at times near confluent, in the head/neck area  (
         <a class="graphic graphic_picture graphicRef106141" href="/z/d/graphic/106141.html" rel="external">
          picture 4
         </a>
         ).
        </p>
        <p>
         Other skin lesions initially described in BHD syndrome along with fibrofolliculomas include trichodiscomas and acrochordons. Trichodiscomas are clinically indistinguishable from fibrofolliculomas and may represent a histologic variant of the same tumor  (
         <a class="graphic graphic_picture graphicRef98472" href="/z/d/graphic/98472.html" rel="external">
          picture 5
         </a>
         ). Acrochordons (skin tags) are common in the general population, and their presence or absence is not helpful in making/excluding a diagnosis of BHD syndrome. Angiofibromas (also known as fibrous papules) may occasionally be seen in the setting of BHD syndrome but are also common in the general population [
         <a href="#rid12">
          12
         </a>
         ]. The presence of multiple facial angiofibromata should raise suspicion of tuberous sclerosis complex (TSC)  (
         <a class="graphic graphic_picture graphicRef54868" href="/z/d/graphic/54868.html" rel="external">
          picture 6
         </a>
         ). (See
         <a class="local">
          'Differential diagnosis'
         </a>
         below.)
        </p>
        <p>
         Small, mucosa-colored or whitish papules on the gingiva, tongue, mucosal lips  (
         <a class="graphic graphic_picture graphicRef106341" href="/z/d/graphic/106341.html" rel="external">
          picture 7
         </a>
         ), or buccal mucosa have been reported in some patients with BHD syndrome [
         <a href="#rid13">
          13
         </a>
         ]. However, similar lesions may be seen in a variety of hamartoma syndromes, such as multiple endocrine neoplasia I, TSC, and Cowden disease [
         <a href="#rid14">
          14,15
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H25197043">
         <span class="h2">
          Pulmonary manifestations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Multiple, bilateral pulmonary cysts develop in 70 to 80 percent of affected members of families with BHD syndrome and may be the only manifestation of the disease [
         <a href="#rid5">
          5,16
         </a>
         ]. Approximately 30 percent of patients with pulmonary cysts develop single or more often multiple episodes of spontaneous pneumothorax, usually before the age of 40 years [
         <a href="#rid3">
          3,17
         </a>
         ]. Despite the high frequency of pulmonary involvement, most patients with BHD syndrome have normal pulmonary function or mild obstructive pulmonary disease [
         <a href="#rid5">
          5
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/112259.html" rel="external">
          "Diagnostic approach to the adult with cystic lung disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2019191037">
         <span class="h3">
          Radiologic findings
         </span>
         <span class="headingEndMark">
          —
         </span>
         High-resolution chest computed tomography (HRCT) scans show numerous, irregularly shaped, thin-walled pulmonary cysts, most of which are &lt;1 cm in size [
         <a href="#rid18">
          18
         </a>
         ]. In contrast with the typical apical location of air blebs seen in patients with spontaneous primary pneumothorax or pneumothorax secondary to chronic obstructive pulmonary disease (COPD), the majority of cysts in patients with BHD syndrome are located in the basilar medial regions of the lungs [
         <a href="#rid18">
          18
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6706.html" rel="external">
          "Pneumothorax in adults: Epidemiology and etiology"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6691.html" rel="external">
          "Treatment of secondary spontaneous pneumothorax in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H25197049">
         <span class="h2">
          Kidney tumors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Renal cancer is the most serious manifestation of BHD syndrome, occurring in approximately 12 to 34 percent of patients around the age of 50 years (range 30 to 70 years) [
         <a href="#rid3">
          3,17,19,20
         </a>
         ]. In contrast with other inherited renal cancer syndromes, which are usually associated with a single histologic tumor type, BHD syndrome is associated with a wide range of tumor histologies, most commonly chromophobe tumors and hybrid chromophobe/oncocytic tumors. Clear cell carcinoma, papillary carcinoma, and mixed-type carcinoma may infrequently be seen [
         <a href="#rid1">
          1
         </a>
         ]. Renal oncocytosis, consisting of diffuse microscopic nodules of oncocytes, which are large, well-differentiated neoplastic cells, have also been observed in kidney parenchyma in the majority of patients with BHD syndrome and renal tumors.
        </p>
        <p class="headingAnchor" id="H25197061">
         <span class="h2">
          Other neoplasms
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although early reports suggested an association between BHD syndrome and colon polyposis and colorectal carcinoma [
         <a href="#rid21">
          21
         </a>
         ], the analysis of a United States-based cohort including 223 members of 33 families with BHD syndrome did not find an increased risk of colon polyps or colorectal cancer [
         <a href="#rid2">
          2
         </a>
         ]. However, a United Kingdom study of 51 families with BHD syndrome identified an elevated risk of colorectal cancer in patients with BHD syndrome and a specific c.1285dupC variant in the
         <em>
          FLCN
         </em>
         gene [
         <a href="#rid22">
          22
         </a>
         ]. A German study of 256 BHD syndrome patients from 83 families found a prevalence rate of colon cancer of 5.1 percent [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p>
         There are isolated reports of a variety of cutaneous and internal tumors in patients with BHD syndrome, including lipomas; cutaneous cysts; melanoma; and parotid, thyroid, and parathyroid tumors [
         <a href="#rid24">
          24-28
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3838862973">
         <span class="h2">
          Clinical associations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Concurrent features of BHD syndrome (eg, renal cell carcinomas and/or evidence of cutaneous fibrofolliculomas) have been described in a few patients with Smith-Magenis syndrome, a developmental disorder associated with cognitive impairment caused by microdeletion of 17p11.2, with resultant haploinsufficiency of the retinoic acid-induced 1 (
         <em>
          RA1
         </em>
         ) gene as well as of
         <em>
          FLCN
         </em>
         located in the deleted region [
         <a href="#rid29">
          29,30
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/16648.html" rel="external">
          "Microdeletion syndromes (chromosomes 12 to 22)", section on '17p11.2 deletion syndrome (Smith-Magenis syndrome)'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H25197067">
         <span class="h1">
          PATHOLOGY
         </span>
        </p>
        <p class="headingAnchor" id="H1918059267">
         <span class="h2">
          Skin
         </span>
         <span class="headingEndMark">
          —
         </span>
         Fibrofolliculoma, a benign hamartoma of the hair follicle, is the hallmark skin finding of Birt-Hogg-Dubé (BHD) syndrome. Fibrofolliculoma is typically characterized by thin, epithelial strands two to four cell layers thick that emanate from an adjacent hair follicle. The epithelial strands often anastomose with one another in a background of stromal mucin and fibrocytes  (
         <a class="graphic graphic_picture graphicRef106171" href="/z/d/graphic/106171.html" rel="external">
          picture 8
         </a>
         ). In trichodiscomas, the myxoid stroma is the most prominent feature, and the pilosebaceous units, if present, are at the periphery of the lesion  (
         <a class="graphic graphic_picture graphicRef98295" href="/z/d/graphic/98295.html" rel="external">
          picture 9
         </a>
         ) [
         <a href="#rid31">
          31
         </a>
         ]. However, it is unclear whether trichodiscomas and fibrofolliculomas in fact represent discrete histopathologic entities. Features of both trichodiscoma and fibrofolliculoma, which are both derived from epithelial and mesenchymal components, can often be identified in a single biopsy. In patients with BHD syndrome, histologic features of fibrofolliculoma have been demonstrated in lesions clinically resembling acrochordons [
         <a href="#rid32">
          32
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/16910.html" rel="external">
          "Cutaneous adnexal tumors", section on 'Trichodiscoma and fibrofolliculoma'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H324253067">
         <span class="h2">
          Lung
         </span>
         <span class="headingEndMark">
          —
         </span>
         The histopathologic examination of lung specimens of 11 patients with BHD syndrome and history of pulmonary cysts and recurrent pneumothorax showed that the inner surfaces of the pulmonary cysts were lined with cytokeratin-positive, type II pneumocyte-like cells [
         <a href="#rid33">
          33
         </a>
         ]. This finding suggests that, in contrast with nonspecific blebs or bullae, which result from alveolar destruction, the BHD syndrome pulmonary cysts may be considered slowly growing, hamartomatous cysts that may frequently rupture. In all cases, the epithelial cells in the pulmonary cysts stained positive for folliculin (FLCN) expression, suggesting that FLCN exists in a haploinsufficient form in cyst-lining epithelial cells.
        </p>
        <p class="headingAnchor" id="H4133882050">
         <span class="h2">
          Kidney
         </span>
         <span class="headingEndMark">
          —
         </span>
         BHD syndrome is remarkable for the histologic variability of renal tumors. Chromophobe and mixed chromophobe-oncocytic patterns are most common, but papillary and clear cell histologic patterns may also be seen. Patients may have multiple tumors in the same kidney or in the contralateral kidney. In one review of 130 renal tumors from 30 patients with BHD syndrome, 50 percent were hybrid tumors with elements of oncocytoma and chromophobe renal cell carcinoma, 34 percent were chromophobe renal cell carcinoma, 9 percent clear cell renal cell carcinoma, 5 percent oncocytomas, and 2 percent papillary renal cell carcinoma [
         <a href="#rid20">
          20
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2982.html" rel="external">
          "Epidemiology, pathology, and pathogenesis of renal cell carcinoma"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H25197073">
         <span class="h1">
          DIAGNOSIS
         </span>
        </p>
        <p class="headingAnchor" id="H1083655228">
         <span class="h2">
          Clinical suspicion
         </span>
         <span class="headingEndMark">
          —
         </span>
         In approximately 90 percent of patients with Birt-Hogg-Dubé (BHD) syndrome, cutaneous fibrofolliculomas and trichodiscomas are the first and most consistent manifestation of the disease. Thus, the diagnosis of BHD syndrome should be suspected in any patient presenting with multiple facial papules that have been histologically proven to be fibrofolliculomas. A personal or family history of lung cysts, especially if located in the basilar medial regions of the lungs, or pneumothorax, especially if recurrent, and/or a family or personal history of renal cancer at a young age should raise suspicion of BHD syndrome, even in the absence of cutaneous lesions. Patients and family members with suspected BHD syndrome should undergo further clinical evaluation and imaging studies for kidney lesions and be offered genetic testing for diagnostic confirmation.
        </p>
        <p class="headingAnchor" id="H605628377">
         <span class="h2">
          Skin biopsy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Skin biopsy is indicated in all patients presenting with multiple facial papules suspected to be fibrofolliculomas. A punch biopsy is preferred to a shave biopsy because it allows the visualization of the entire lesion and associated hair follicle.
        </p>
        <p class="headingAnchor" id="H3296856308">
         <span class="h2">
          Imaging studies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Serial baseline chest and abdominal imaging should be obtained in patients suspected to have BHD syndrome. High-resolution chest computed tomography (HRCT) will identify cysts within the lung or occult pneumothoraces (see
         <a class="local">
          'Radiologic findings'
         </a>
         above). Abdominal CT or MRI with intravenous contrast provide the best anatomic detail of the kidneys and allow for characterization of any cystic or solid renal lesions.
        </p>
        <p class="headingAnchor" id="H2881415897">
         <span class="h2">
          Genetic testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         Germline pathogenic variants in the folliculin (
         <em>
          FLCN
         </em>
         ) can be detected by sequence analysis of the entire coding region of
         <em>
          FLCN
         </em>
         and confirm the diagnosis of BHD syndrome. Disease variants in the
         <em>
          FLCN
         </em>
         gene were detected in 88 percent of families in the National Cancer Institute BHD syndrome cohort by sequence analysis of all 14 exons [
         <a href="#rid3">
          3
         </a>
         ]. If full gene sequence analysis does not identify a pathogenic variant, deletion/duplication analysis (ie, copy number analysis) may be considered [
         <a href="#rid34">
          34
         </a>
         ]. In one study of families with BHD syndrome lacking
         <em>
          FLCN
         </em>
         sequence alterations, intragenic deletions and/or duplications in
         <em>
          FLCN
         </em>
         were identified in 11 of 23 patients in whom a pathogenic variant could not be detected by sequence analysis [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H106400022">
         <span class="h2">
          Diagnostic criteria
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of BHD syndrome is made based upon the presence of one or more of the following proposed criteria [
         <a href="#rid5">
          5
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Presence of ≥2 skin lesions clinically consistent with fibrofolliculoma and/or trichodiscoma and ≥1 histologically confirmed fibrofolliculoma
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Multiple bilateral pulmonary cysts located primarily in the basilar regions of the lung with or without a history of spontaneous pneumothorax before age 40 years, especially if associated with a family history of similar pulmonary manifestations
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Bilateral, multifocal chromophobe renal carcinomas or hybrid oncocytic tumors, especially in patients with a family history of renal tumors at &lt;50 years
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A combination of these cutaneous, pulmonary, or renal manifestations presenting in the patient or family members
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Identification of a germline pathogenic variant in
         <em>
          FLCN
         </em>
         by deoxyribonucleic acid (DNA) sequencing
        </p>
        <p>
        </p>
        <p>
         Although genetic testing will identify a germline
         <em>
          FLCN
         </em>
         variant and confirm the diagnosis in approximately 90 percent of cases, in some patients, the diagnosis of BHD syndrome relies upon clinicopathologic findings.
        </p>
        <p class="headingAnchor" id="H3297309623">
         <span class="h1">
          GENETIC COUNSELING
         </span>
         <span class="headingEndMark">
          —
         </span>
         Once a folliculin (
         <em>
          FLCN
         </em>
         ) variant has been demonstrated in a proband, genetic testing and counseling should be offered to at-risk relatives (ie, all first-degree relatives), and carriers of the germline variant should be offered imaging surveillance for renal cancer. Genetic testing of family members at risk of Birt-Hogg-Dubé (BHD) syndrome is recommended starting at age 20 to 21 years [
         <a href="#rid1">
          1,36
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H25197079">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
        </p>
        <p class="headingAnchor" id="H3618306827">
         <span class="h2">
          Skin lesions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cutaneous neoplasms that mimic clinically the fibrofolliculomas of Birt-Hogg-Dubé (BHD) syndrome may occur sporadically or in other cancer-associated genodermatoses:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Fibrous papules of the nose
         </strong>
         – Fibrous papules of the nose (also called fibrous papules of the face or facial angiofibromas) are skin-colored to white, firm, 1 to 3 mm papules that usually occur singly or in small numbers, often on the nose or midface, in late adulthood  (
         <a class="graphic graphic_picture graphicRef106159 graphicRef106160" href="/z/d/graphic/106159.html" rel="external">
          picture 10A-B
         </a>
         ). Histologically, these lesions resemble angiofibromas and show a normal epidermis, sometimes with an increased number of clear cells overlying the lesion, increased dermal collagen with ectatic blood vessels, and increased dermal cellularity composed of mono- and multinucleated cells with a histiocyte-like appearance.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Sebaceous hyperplasia
         </strong>
         – Sebaceous hyperplasia presents as 1 to 4 mm lobulated papules with a yellow hue, often on the forehead and cheeks of older individuals  (
         <a class="graphic graphic_picture graphicRef98389" href="/z/d/graphic/98389.html" rel="external">
          picture 11
         </a>
         and
         <a class="graphic graphic_picture graphicRef98390" href="/z/d/graphic/98390.html" rel="external">
          picture 12
         </a>
         ). Histology shows a dome-shaped lesion with numerous, mature sebaceous lobules composed of mature sebocytes, frequently radiating from a central, dilated hair follicle. (See
         <a class="medical medical_review" href="/z/d/html/16910.html" rel="external">
          "Cutaneous adnexal tumors", section on 'Sebaceous hyperplasia'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Tuberous sclerosis complex
         </strong>
         – Tuberous sclerosis complex (TSC) presents in childhood with multiple fibrous papules with an erythematous appearance known as angiofibromas. These lesions, also referred to as "adenoma sebaceum," cluster on the midface  (
         <a class="graphic graphic_picture graphicRef54868" href="/z/d/graphic/54868.html" rel="external">
          picture 6
         </a>
         ). Other skin features of TSC, including periungual fibromas, shagreen patch, confetti spots, and ash leaf macules, are not present in BHD syndrome. (See
         <a class="medical medical_review" href="/z/d/html/6175.html" rel="external">
          "Tuberous sclerosis complex: Clinical features"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Brooke-Spiegler syndrome
         </strong>
         – Brooke-Spiegler syndrome (multiple hereditary trichoepitheliomas) presents with multiple, skin-colored papules located on the face  (
         <a class="graphic graphic_picture graphicRef98305" href="/z/d/graphic/98305.html" rel="external">
          picture 13
         </a>
         ) and particularly in the nasolabial sulcus, leading to a "heaped up" appearance  (
         <a class="graphic graphic_picture graphicRef106161" href="/z/d/graphic/106161.html" rel="external">
          picture 14
         </a>
         ). Histology can differentiate trichoepithelioma from fibrofolliculoma. (See
         <a class="medical medical_review" href="/z/d/html/15522.html" rel="external">
          "Brooke-Spiegler syndrome (
          <i>
           CYLD
          </i>
          cutaneous syndrome)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adenoma sebaceum
         </strong>
         – Sebaceous adenomas present as yellowish or brownish papules, usually &lt;1 cm in diameter, almost exclusively located on the head and neck  (
         <a class="graphic graphic_picture graphicRef98399" href="/z/d/graphic/98399.html" rel="external">
          picture 15
         </a>
         ). Histologically, sebaceous adenoma is composed of well-circumscribed, round aggregations of predominantly mature, lipid-filled sebocytes. The presence of multiple sebaceous adenomas should prompt evaluation for Muir-Torre syndrome, a subtype of hereditary nonpolyposis colorectal cancer syndrome. (See
         <a class="medical medical_review" href="/z/d/html/98605.html" rel="external">
          "Muir-Torre syndrome"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cowden syndrome
         </strong>
         – Cowden syndrome is an autosomal dominant disorder characterized by hamartomatous tumors in multiple organ systems, including the skin, and an increased risk for malignancy. The facial trichilemmomas in Cowden syndrome are more keratotic in appearance than fibrofolliculomas seen in BHD syndrome  (
         <a class="graphic graphic_picture graphicRef98306" href="/z/d/graphic/98306.html" rel="external">
          picture 16
         </a>
         ). Macrocephaly, acral keratoses, and oral papillomas  (
         <a class="graphic graphic_picture graphicRef60952" href="/z/d/graphic/60952.html" rel="external">
          picture 17
         </a>
         ) are found in Cowden syndrome but not in BHD syndrome [
         <a href="#rid37">
          37
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/16543.html" rel="external">
          "PTEN hamartoma tumor syndromes, including Cowden syndrome", section on 'Cowden syndrome'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Generalized basaloid follicular hamartoma syndrome
         </strong>
         – Generalized basaloid follicular hamartoma syndrome is a rare, autosomal dominant disorder characterized by numerous, small, skin-colored and hyperpigmented facial and upper trunk papules with milia and comedo-like lesions; alopecia or hypotrichosis; and hypohidrosis [
         <a href="#rid38">
          38
         </a>
         ]. Histologically, the papular lesions are follicular hamartomas that mimic infundibulocystic basal cell carcinoma, a subtype of basal cell carcinoma with follicular differentiation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Familial multiple discoid fibromas
         </strong>
         – Familial multiple discoid fibromas is characterized by the development of multiple trichodiscoma-like lesions at an early age (birth to 25 years) on the face, with predominant involvement on the ears. Because typical histology of fibrofolliculoma is not seen, the term "discoid fibromas" was proposed to denote their distinct pathologic appearance. Folliculin (
         <em>
          FLCN
         </em>
         ) variants, pulmonary cysts, or renal neoplasms have not been reported in this syndrome [
         <a href="#rid39">
          39,40
         </a>
         ]. A locus on chromosome 5 containing
         <em>
          FNIP1
         </em>
         has been implicated in the syndrome [
         <a href="#rid41">
          41
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/16910.html" rel="external">
          "Cutaneous adnexal tumors"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Lipomatosis, fibrofolliculomas, and renal cell carcinoma
         </strong>
         – A report described a family with overlapping features of BHD syndrome, specifically oral mucosal lesions, fibrofolliculomas, and renal cell carcinoma [
         <a href="#rid42">
          42
         </a>
         ]. In contrast to BHD syndrome, most patients exhibited prominent cutaneous lipomatosis, and all patients lacked pulmonary cysts. A missense variant in
         <em>
          PRDM10
         </em>
         was identified that cosegregated with the phenotype [
         <a href="#rid42">
          42
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1063526859">
         <span class="h2">
          Lung cysts and recurrent pneumothorax
         </span>
         <span class="headingEndMark">
          —
         </span>
         The differential diagnosis of lung manifestations associated with BHD syndrome includes:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Lymphangioleiomyomatosis
         </strong>
         – Lymphangioleiomyomatosis (LAM) is a rare lung disease that may be sporadic or associated with the TSC. It predominantly affects young women and is characterized by the presence of diffuse, small, thin-walled cysts scattered throughout both lung fields. The definitive diagnosis requires the demonstration on a lung biopsy of interstitial nodular proliferations of atypical smooth muscle cells. (See
         <a class="medical medical_review" href="/z/d/html/4335.html" rel="external">
          "Sporadic lymphangioleiomyomatosis: Epidemiology and pathogenesis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Emphysema
         </strong>
         – Spontaneous pneumothorax occurs frequently in patients with chronic obstructive pulmonary disease (COPD). The presence of symptoms compatible with COPD, pulmonary function testing revealing airflow obstruction, and the absence of true thin-walled cysts on high-resolution computed tomography (HRCT) lead to the correct diagnosis. (See
         <a class="medical medical_review" href="/z/d/html/1455.html" rel="external">
          "Chronic obstructive pulmonary disease: Diagnosis and staging"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6691.html" rel="external">
          "Treatment of secondary spontaneous pneumothorax in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pulmonary Langerhans cell histiocytosis
         </strong>
         – Pulmonary Langerhans cell histiocytosis is an uncommon interstitial lung disease that primarily affects young adults. The diagnosis is based upon the finding on HRCT of multiple cysts and nodules with upper lobe predominance and interstitial thickening. (See
         <a class="medical medical_review" href="/z/d/html/4334.html" rel="external">
          "Pulmonary Langerhans cell histiocytosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1210692411">
         <span class="h2">
          Renal tumors
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Sporadic hybrid chromophobe/oncocytic tumors
         </strong>
         – There are no specific immunohistochemical markers to differentiate chromophobe tumors and hybrid chromophobe/oncocytic tumors associated with BHD syndrome from their sporadic counterpart. However, BHD syndrome-associated tumors and sporadic tumors may present several differences in gene expression and genetic aberrations [
         <a href="#rid43">
          43-45
         </a>
         ]. While
         <em>
          FLCN
         </em>
         gene variants can be detected in hybrid chromophobe/oncocytic tumors in patients with BHD syndrome, they are absent in sporadic tumors and in tumors associated with renal oncocytosis. (See
         <a class="medical medical_review" href="/z/d/html/2982.html" rel="external">
          "Epidemiology, pathology, and pathogenesis of renal cell carcinoma", section on 'Pathology'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hereditary leiomyomatosis and renal cell cancer
         </strong>
         – In hereditary leiomyomatosis and renal cell cancer (HLRCC), renal tumors are typically solitary and unilateral. These tumors are in most cases type 2 papillary renal cell carcinomas and tend to be aggressive, with rapid nodal and distant dissemination. (See
         <a class="medical medical_review" href="/z/d/html/15516.html" rel="external">
          "Hereditary leiomyomatosis and renal cell cancer (HLRCC)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2948.html" rel="external">
          "Hereditary kidney cancer syndromes"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Von Hippel-Lindau disease
         </strong>
         – Von Hippel-Lindau (VHL) disease is an inherited, autosomal dominant syndrome characterized by a variety of benign and malignant tumors, including renal cancer. In contrast with BHD syndrome, virtually all VHL-associated renal cancers are clear cell tumors. (See
         <a class="medical medical_review" href="/z/d/html/5193.html" rel="external">
          "Clinical features, diagnosis, and management of von Hippel-Lindau disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H25197085">
         <span class="h1">
          MANAGEMENT
         </span>
        </p>
        <p class="headingAnchor" id="H3117850047">
         <span class="h2">
          Skin lesions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Fibrofolliculomas and trichodiscomas are benign lesions that usually do not require treatment. However, some patients with numerous facial lesions may seek treatment because of cosmetic concerns. Destructive therapies, including shave removal, electrodessication with or without curettage, and carbon dioxide (CO
         <sub>
          2
         </sub>
         ) or erbium-doped yttrium aluminum garnet (Er:YAG) laser ablation, have been used in a few patients with good results, although recurrence is commonplace [
         <a href="#rid46">
          46-49
         </a>
         ].
        </p>
        <p>
         In a randomized, split-face trial including 19 patients, topical rapamycin (
         <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">
          sirolimus
         </a>
         ) 0.1% solution did not result in reduction in size or number of fibrofolliculoma lesions compared with placebo [
         <a href="#rid50">
          50
         </a>
         ]. However, a split-face case report found superior benefit to fractional 1540 nm nonablative laser resurfacing on the side treated concurrently with 1% topical rapamycin ointment, suggesting that drug delivery may be improved by combination therapy [
         <a href="#rid51">
          51
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3363701404">
         <span class="h2">
          Pneumothorax
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment of pneumothorax in patients with Birt-Hogg-Dubé (BHD) syndrome is the same as in patients with secondary pneumothorax (see
         <a class="medical medical_review" href="/z/d/html/6691.html" rel="external">
          "Treatment of secondary spontaneous pneumothorax in adults"
         </a>
         ). To limit recurrence (eg, in the contralateral lung), patients should avoid tobacco use and SCUBA (self-contained underwater breathing apparatus) diving [
         <a href="#rid52">
          52
         </a>
         ]. Risks of pneumothorax during air travel are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/6705.html" rel="external">
          "Pneumothorax and air travel"
         </a>
         .)
        </p>
        <p>
         Pulmonary assessment is recommended for patients with BHD syndrome undergoing surgery, and excessive positive pressure ventilation should be avoided intraoperatively to avoid rupture of a pulmonary cyst and pneumothorax [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2834180049">
         <span class="h2">
          Renal tumors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Surgery is the only treatment option for BHD syndrome-associated renal tumors. The most common BHD syndrome tumors, chromophobe and hybrid oncocytic tumors, tend to be indolent. Experts recommend active surveillance, as long as the dominant lesion is less than 3 cm in diameter, and nephron-sparing surgery for tumors that are ≥3 cm in size, along with the removal of all lesions detected intraoperatively [
         <a href="#rid36">
          36
         </a>
         ]. Renal preservation is particularly important for patients with BHD syndrome, given the potential for multiple renal tumors and the risk of developing chronic renal failure following surgery. (See
         <a class="medical medical_review" href="/z/d/html/2948.html" rel="external">
          "Hereditary kidney cancer syndromes", section on 'Birt-Hogg-Dubé syndrome'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2126578051">
         <span class="h2">
          Surveillance
         </span>
         <span class="headingEndMark">
          —
         </span>
         Lifelong surveillance for renal cancer is needed for patients with BHD syndrome. However, there is no clinical consensus on the optimal surveillance interval. Some experts recommend abdominal imaging starting at age 21 (or following diagnosis) and at least every 36 months until a mass is identified, at which time interval imaging is determined in the individual patient based upon the size and growth rate of the tumor [
         <a href="#rid36">
          36
         </a>
         ]. Ultrasonography may miss small isoechoic renal masses, and therefore, CT imaging or MRI to minimize radiation exposure should be used when possible [
         <a href="#rid53">
          53
         </a>
         ]. Regular skin cancer screening is reasonable given the possible association with melanoma. Repeat pulmonary screening after initial diagnosis is recommended if new respiratory symptoms develop.
        </p>
        <p class="headingAnchor" id="H25197091">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The prognosis of Birt-Hogg-Dubé (BHD) syndrome depends primarily upon the penetrance of renal cancer and histologic type of renal tumors that develop. Deaths from renal cancer in BHD syndrome undergoing routine surveillance are uncommon, and the majority of deaths from metastatic disease are due to clear cell carcinoma tumors [
         <a href="#rid54">
          54,55
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2982.html" rel="external">
          "Epidemiology, pathology, and pathogenesis of renal cell carcinoma"
         </a>
         .)
        </p>
        <p>
         Patients should be reassured that BHD syndrome cystic lung disease typically does not result in compromised respiratory function [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H25197103">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definition and pathogenesis
         </strong>
         – Birt-Hogg-Dubé (BHD) syndrome is an autosomal dominant condition characterized by benign skin hamartomas, most commonly located on the head and neck, pulmonary cysts and spontaneous pneumothorax, and an increased risk of renal cancer. BHD syndrome is caused by germline pathogenic variants in the folliculin (
         <em>
          FLCN
         </em>
         ) gene, located on chromosome 17p11.2. (See
         <a class="local">
          'Introduction'
         </a>
         above and
         <a class="local">
          'Pathogenesis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical manifestations
         </strong>
         – The phenotype of BHD syndrome is highly heterogeneous:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Skin lesions
         </strong>
         – Fibrofolliculomas, presenting as round, white-gray papules 1 to 4 mm in size located on the head and neck region, are typically the earliest and most frequent manifestation of BHD syndrome  (
         <a class="graphic graphic_picture graphicRef106138 graphicRef106140" href="/z/d/graphic/106138.html" rel="external">
          picture 2A-B
         </a>
         ). (See
         <a class="local">
          'Cutaneous lesions'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Pulmonary manifestations
         </strong>
         – Pulmonary manifestations include multiple bilateral pulmonary cysts and spontaneous pneumothorax before age 40 years. (See
         <a class="local">
          'Pulmonary manifestations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Kidney tumors
         </strong>
         – Renal cancer is the most serious manifestation of BHD syndrome, occurring in approximately one-third of affected patients at a mean age of 50 years. The histology of renal tumors varies, with chromophobe tumors and hybrid chromophobe/oncocytic tumors occurring in most cases. (See
         <a class="local">
          'Kidney tumors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – The diagnosis of BHD syndrome is made based upon a combination of cutaneous, pulmonary, or renal manifestations presenting in the patient or family members and the identification of a germline pathogenic variant in
         <em>
          FLCN
         </em>
         by DNA sequencing. (See
         <a class="local">
          'Diagnosis'
         </a>
         above and
         <a class="local">
          'Diagnostic criteria'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management
         </strong>
         – The management of patients with BHD syndrome is primarily directed at the detection and treatment of renal tumors and pulmonary manifestations. Treatment of pneumothorax in patients with BHD syndrome is the same as in patients with secondary pneumothorax. (See
         <a class="medical medical_review" href="/z/d/html/6691.html" rel="external">
          "Treatment of secondary spontaneous pneumothorax in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Surgery is the only treatment option for BHD syndrome-associated renal tumors (see
         <a class="medical medical_review" href="/z/d/html/15719.html" rel="external">
          "Overview of the treatment of renal cell carcinoma"
         </a>
         ). Because of the indolent behavior of the most common BHD syndrome tumors, chromophobe and hybrid oncocytic tumors, some experts recommend active surveillance, as long as the dominant lesion is less than 3 cm in diameter, and nephron-sparing surgery for tumors that are ≥3 cm in size, along with the removal of all lesions detected intraoperatively. (See
         <a class="local">
          'Renal tumors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Surveillance for kidney cancer
         </strong>
         – Lifelong surveillance for renal cancer is needed for patients with BHD syndrome. Some experts recommend abdominal imaging with CT or MRI after diagnosis and at least every 36 months thereafter, unless a mass is identified, at which time interval imaging is determined in the individual patient based upon the size and growth rate of the tumor. (See
         <a class="local">
          'Surveillance'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1214380512">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The views expressed in this topic are those of the author(s) and do not reflect the official views or policy of the National Institutes of Health or the United States Government or its components.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Menko FH, van Steensel MA, Giraud S, et al. Birt-Hogg-Dubé syndrome: diagnosis and management. Lancet Oncol 2009; 10:1199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zbar B, Alvord WG, Glenn G, et al. Risk of renal and colonic neoplasms and spontaneous pneumothorax in the Birt-Hogg-Dubé syndrome. Cancer Epidemiol Biomarkers Prev 2002; 11:393.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Toro JR, Wei MH, Glenn GM, et al. BHD mutations, clinical and molecular genetic investigations of Birt-Hogg-Dubé syndrome: a new series of 50 families and a review of published reports. J Med Genet 2008; 45:321.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lim DH, Rehal PK, Nahorski MS, et al. A new locus-specific database (LSDB) for mutations in the folliculin (FLCN) gene. Hum Mutat 2010; 31:E1043.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schmidt LS, Linehan WM. Molecular genetics and clinical features of Birt-Hogg-Dubé syndrome. Nat Rev Urol 2015; 12:558.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vocke CD, Yang Y, Pavlovich CP, et al. High frequency of somatic frameshift BHD gene mutations in Birt-Hogg-Dubé-associated renal tumors. J Natl Cancer Inst 2005; 97:931.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baba M, Hong SB, Sharma N, et al. Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling. Proc Natl Acad Sci U S A 2006; 103:15552.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hasumi H, Baba M, Hasumi Y, et al. Folliculin-interacting proteins Fnip1 and Fnip2 play critical roles in kidney tumor suppression in cooperation with Flcn. Proc Natl Acad Sci U S A 2015; 112:E1624.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Warren MB, Torres-Cabala CA, Turner ML, et al. Expression of Birt-Hogg-Dubé gene mRNA in normal and neoplastic human tissues. Mod Pathol 2004; 17:998.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Steensel MA, Verstraeten VL, Frank J, et al. Novel mutations in the BHD gene and absence of loss of heterozygosity in fibrofolliculomas of Birt-Hogg-Dubé patients. J Invest Dermatol 2007; 127:588.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aivaz O, Berkman S, Middelton L, et al. Comedonal and Cystic Fibrofolliculomas in Birt-Hogg-Dube Syndrome. JAMA Dermatol 2015; 151:770.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DiCicco B, Johnson W, Allred J, et al. Koenen's tumor and facial angiofibromas in a case of Birt-Hogg-Dubé syndrome: A cutaneous contribution to growing evidence of a relationship with tuberous sclerosis complex. JAAD Case Rep 2016; 2:196.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kluger N, Giraud S, Coupier I, et al. Birt-Hogg-Dubé syndrome: clinical and genetic studies of 10 French families. Br J Dermatol 2010; 162:527.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Toro JR, Glenn G, Duray P, et al. Birt-Hogg-Dubé syndrome: a novel marker of kidney neoplasia. Arch Dermatol 1999; 135:1195.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nadershahi NA, Wescott WB, Egbert B. Birt-Hogg-Dubé syndrome: a review and presentation of the first case with oral lesions. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997; 83:496.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gunji Y, Akiyoshi T, Sato T, et al. Mutations of the Birt Hogg Dube gene in patients with multiple lung cysts and recurrent pneumothorax. J Med Genet 2007; 44:588.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schmidt LS, Nickerson ML, Warren MB, et al. Germline BHD-mutation spectrum and phenotype analysis of a large cohort of families with Birt-Hogg-Dubé syndrome. Am J Hum Genet 2005; 76:1023.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gupta N, Seyama K, McCormack FX. Pulmonary manifestations of Birt-Hogg-Dubé syndrome. Fam Cancer 2013; 12:387.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pavlovich CP, Grubb RL 3rd, Hurley K, et al. Evaluation and management of renal tumors in the Birt-Hogg-Dubé syndrome. J Urol 2005; 173:1482.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pavlovich CP, Walther MM, Eyler RA, et al. Renal tumors in the Birt-Hogg-Dubé syndrome. Am J Surg Pathol 2002; 26:1542.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hornstein OP, Knickenberg M. Perifollicular fibromatosis cutis with polyps of the colon--a cutaneo-intestinal syndrome sui generis. Arch Dermatol Res 1975; 253:161.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nahorski MS, Lim DH, Martin L, et al. Investigation of the Birt-Hogg-Dube tumour suppressor gene (FLCN) in familial and sporadic colorectal cancer. J Med Genet 2010; 47:385.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sattler EC, Syunyaeva Z, Reithmair M, et al. Colorectal cancer risk in families with Birt-Hogg-Dubé syndrome increased. Eur J Cancer 2021; 151:168.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mota-Burgos A, Acosta EH, Márquez FV, et al. Birt-Hogg-Dubé syndrome in a patient with melanoma and a novel mutation in the FCLN gene. Int J Dermatol 2013; 52:323.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chung JY, Ramos-Caro FA, Beers B, et al. Multiple lipomas, angiolipomas, and parathyroid adenomas in a patient with Birt-Hogg-Dube syndrome. Int J Dermatol 1996; 35:365.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lindor NM, Kasperbauer J, Lewis JE, Pittelkow M. Birt-Hogg-Dube syndrome presenting as multiple oncocytic parotid tumors. Hered Cancer Clin Pract 2012; 10:13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu V, Kwan T, Page EH. Parotid oncocytoma in the Birt-Hogg-Dubé syndrome. J Am Acad Dermatol 2000; 43:1120.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mikesell KV, Kulaylat AN, Donaldson KJ, et al. A rare soft tissue tumor masquerading as a parathyroid adenoma in a patient with birt-hogg-dubé syndrome and multiple cervical endocrinopathies. Case Rep Pathol 2014; 2014:753694.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vocke CD, Fleming LR, Piskorski AM, et al. A diagnosis of Birt-Hogg-Dubé syndrome in individuals with Smith-Magenis syndrome: Recommendation for cancer screening. Am J Med Genet A 2023; 191:490.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dardour L, Verleyen P, Lesage K, et al. Bilateral renal tumors in an adult man with Smith-Magenis syndrome: The role of the FLCN gene. Eur J Med Genet 2016; 59:499.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sidhu HK, Patel RV, Goldenberg G. Dermatology clinics: what's new in dermatopathology: news in nonmelanocytic neoplasia. Dermatol Clin 2012; 30:623.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De la Torre C, Ocampo C, Doval IG, et al. Acrochordons are not a component of the Birt-Hogg-Dubé syndrome: does this syndrome exist? Case reports and review of the literature. Am J Dermatopathol 1999; 21:369.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Furuya M, Tanaka R, Koga S, et al. Pulmonary cysts of Birt-Hogg-Dubé syndrome: a clinicopathologic and immunohistochemical study of 9 families. Am J Surg Pathol 2012; 36:589.
          </a>
         </li>
         <li class="breakAll">
          Toro JR. Birt-Hogg-Dubé syndrome. In: GeneReviews, Adam MP, Ardinger HH, Pagon RA, et al. (Eds), University of Washington, Seattle, WA 1993.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Benhammou JN, Vocke CD, Santani A, et al. Identification of intragenic deletions and duplication in the FLCN gene in Birt-Hogg-Dubé syndrome. Genes Chromosomes Cancer 2011; 50:466.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stamatakis L, Metwalli AR, Middelton LA, Marston Linehan W. Diagnosis and management of BHD-associated kidney cancer. Fam Cancer 2013; 12:397.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vincent A, Farley M, Chan E, James WD. Birt-Hogg-Dubé syndrome: a review of the literature and the differential diagnosis of firm facial papules. J Am Acad Dermatol 2003; 49:698.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wheeler CE Jr, Carroll MA, Groben PA, et al. Autosomal dominantly inherited generalized basaloid follicular hamartoma syndrome: report of a new disease in a North Carolina family. J Am Acad Dermatol 2000; 43:189.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Starink TM, Houweling AC, van Doorn MB, et al. Familial multiple discoid fibromas: a look-alike of Birt-Hogg-Dubé syndrome not linked to the FLCN locus. J Am Acad Dermatol 2012; 66:259.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wee JS, Chong H, Natkunarajah J, et al. Familial multiple discoid fibromas: unique histological features and therapeutic response to topical rapamycin. Br J Dermatol 2013; 169:177.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van de Beek I, Glykofridis IE, Tanck MWT, et al. Familial multiple discoid fibromas is linked to a locus on chromosome 5 including the FNIP1 gene. J Hum Genet 2023; 68:273.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van de Beek I, Glykofridis IE, Oosterwijk JC, et al. PRDM10 directs FLCN expression in a novel disorder overlapping with Birt-Hogg-Dubé syndrome and familial lipomatosis. Hum Mol Genet 2023; 32:1223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Furuya M, Hong SB, Tanaka R, et al. Distinctive expression patterns of glycoprotein non-metastatic B and folliculin in renal tumors in patients with Birt-Hogg-Dubé syndrome. Cancer Sci 2015; 106:315.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klomp JA, Petillo D, Niemi NM, et al. Birt-Hogg-Dubé renal tumors are genetically distinct from other renal neoplasias and are associated with up-regulation of mitochondrial gene expression. BMC Med Genomics 2010; 3:59.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hes O, Petersson F, Kuroda N, et al. Renal hybrid oncocytic/chromophobe tumors - a review. Histol Histopathol 2013; 28:1257.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Farrant PB, Emerson R. Letter: hyfrecation and curettage as a treatment for fibrofolliculomas in Birt-Hogg-Dube syndrome. Dermatol Surg 2007; 33:1287.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gambichler T, Wolter M, Altmeyer P, Hoffman K. Treatment of Birt-Hogg-Dubé syndrome with erbium:YAG laser. J Am Acad Dermatol 2000; 43:856.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kahle B, Hellwig S, Schulz T. [Multiple mantleomas in Birt-Hogg-Dubé syndrome: successful therapy with CO2 laser]. Hautarzt 2001; 52:43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pritchard SE, Mahmoudizad R, Parekh PK. Successful treatment of facial papules with electrodessication in a patient with Birt-Hogg-Dubé syndrome. Dermatol Online J 2014; 20.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gijezen LM, Vernooij M, Martens H, et al. Topical rapamycin as a treatment for fibrofolliculomas in Birt-Hogg-Dubé syndrome: a double-blind placebo-controlled randomized split-face trial. PLoS One 2014; 9:e99071.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim D, Wysong A, Teng JM, Rahman Z. Laser-Assisted Delivery of Topical Rapamycin: mTOR Inhibition for Birt-Hogg-Dube Syndrome. Dermatol Surg 2019; 45:1713.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Riel L, van Hulst RA, van Hest L, et al. Recommendations on scuba diving in Birt-Hogg-Dubé syndrome. Expert Rev Respir Med 2023; 17:1003.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jamis-Dow CA, Choyke PL, Jennings SB, et al. Small (&lt; or = 3-cm) renal masses: detection with CT versus US and pathologic correlation. Radiology 1996; 198:785.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Benusiglio PR, Giraud S, Deveaux S, et al. Renal cell tumour characteristics in patients with the Birt-Hogg-Dubé cancer susceptibility syndrome: a retrospective, multicentre study. Orphanet J Rare Dis 2014; 9:163.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Houweling AC, Gijezen LM, Jonker MA, et al. Renal cancer and pneumothorax risk in Birt-Hogg-Dubé syndrome; an analysis of 115 FLCN mutation carriers from 35 BHD families. Br J Cancer 2011; 105:1912.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 100661 Version 16.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19959076" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Birt-Hogg-Dubésyndrome: diagnosis and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11927500" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Risk of renal and colonic neoplasms and spontaneous pneumothorax in the Birt-Hogg-Dubésyndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18234728" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : BHD mutations, clinical and molecular genetic investigations of Birt-Hogg-Dubésyndrome: a new series of 50 families and a review of published reports.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19802896" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : A new locus-specific database (LSDB) for mutations in the folliculin (FLCN) gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26334087" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Molecular genetics and clinical features of Birt-Hogg-Dubésyndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15956655" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : High frequency of somatic frameshift BHD gene mutations in Birt-Hogg-Dubé-associated renal tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17028174" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25775561" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Folliculin-interacting proteins Fnip1 and Fnip2 play critical roles in kidney tumor suppression in cooperation with Flcn.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15143337" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Expression of Birt-Hogg-Dubégene mRNA in normal and neoplastic human tissues.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17124507" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Novel mutations in the BHD gene and absence of loss of heterozygosity in fibrofolliculomas of Birt-Hogg-Dubépatients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25970555" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Comedonal and Cystic Fibrofolliculomas in Birt-Hogg-Dube Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27274535" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Koenen's tumor and facial angiofibromas in a case of Birt-Hogg-Dubésyndrome: A cutaneous contribution to growing evidence of a relationship with tuberous sclerosis complex.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19785621" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Birt-Hogg-Dubésyndrome: clinical and genetic studies of 10 French families.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10522666" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Birt-Hogg-Dubésyndrome: a novel marker of kidney neoplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9127384" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Birt-Hogg-Dubésyndrome: a review and presentation of the first case with oral lesions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17496196" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Mutations of the Birt Hogg Dube gene in patients with multiple lung cysts and recurrent pneumothorax.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15852235" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Germline BHD-mutation spectrum and phenotype analysis of a large cohort of families with Birt-Hogg-Dubésyndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23715758" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Pulmonary manifestations of Birt-Hogg-Dubésyndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15821464" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Evaluation and management of renal tumors in the Birt-Hogg-Dubésyndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12459621" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Renal tumors in the Birt-Hogg-Dubésyndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1200700" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Perifollicular fibromatosis cutis with polyps of the colon--a cutaneo-intestinal syndrome sui generis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20522427" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Investigation of the Birt-Hogg-Dube tumour suppressor gene (FLCN) in familial and sporadic colorectal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34000505" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Colorectal cancer risk in families with Birt-Hogg-Dubésyndrome increased.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23414156" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Birt-Hogg-Dubésyndrome in a patient with melanoma and a novel mutation in the FCLN gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8734663" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Multiple lipomas, angiolipomas, and parathyroid adenomas in a patient with Birt-Hogg-Dube syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23050938" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Birt-Hogg-Dube syndrome presenting as multiple oncocytic parotid tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11100034" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Parotid oncocytoma in the Birt-Hogg-Dubésyndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25610687" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : A rare soft tissue tumor masquerading as a parathyroid adenoma in a patient with birt-hogg-dubésyndrome and multiple cervical endocrinopathies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36513625" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : A diagnosis of Birt-Hogg-Dubésyndrome in individuals with Smith-Magenis syndrome: Recommendation for cancer screening.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27633572" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Bilateral renal tumors in an adult man with Smith-Magenis syndrome: The role of the FLCN gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23021050" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Dermatology clinics: what's new in dermatopathology: news in nonmelanocytic neoplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10446780" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Acrochordons are not a component of the Birt-Hogg-Dubésyndrome: does this syndrome exist? Case reports and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22441547" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Pulmonary cysts of Birt-Hogg-Dubésyndrome: a clinicopathologic and immunohistochemical study of 9 families.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22441547" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Pulmonary cysts of Birt-Hogg-Dubésyndrome: a clinicopathologic and immunohistochemical study of 9 families.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21412933" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Identification of intragenic deletions and duplication in the FLCN gene in Birt-Hogg-Dubésyndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23703644" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Diagnosis and management of BHD-associated kidney cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14512919" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Birt-Hogg-Dubésyndrome: a review of the literature and the differential diagnosis of firm facial papules.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10906638" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Autosomal dominantly inherited generalized basaloid follicular hamartoma syndrome: report of a new disease in a North Carolina family.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21794948" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Familial multiple discoid fibromas: a look-alike of Birt-Hogg-Dubésyndrome not linked to the FLCN locus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23495951" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Familial multiple discoid fibromas: unique histological features and therapeutic response to topical rapamycin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36599954" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Familial multiple discoid fibromas is linked to a locus on chromosome 5 including the FNIP1 gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36440963" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : PRDM10 directs FLCN expression in a novel disorder overlapping with Birt-Hogg-Dubésyndrome and familial lipomatosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25594584" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Distinctive expression patterns of glycoprotein non-metastatic B and folliculin in renal tumors in patients with Birt-Hogg-Dubésyndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21162720" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Birt-Hogg-Dubérenal tumors are genetically distinct from other renal neoplasias and are associated with up-regulation of mitochondrial gene expression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23740406" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Renal hybrid oncocytic/chromophobe tumors - a review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17903168" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Letter: hyfrecation and curettage as a treatment for fibrofolliculomas in Birt-Hogg-Dube syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11050594" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Treatment of Birt-Hogg-Dubésyndrome with erbium:YAG laser.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11220238" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : [Multiple mantleomas in Birt-Hogg-Dubésyndrome: successful therapy with CO2 laser].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25046466" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Successful treatment of facial papules with electrodessication in a patient with Birt-Hogg-Dubésyndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24910976" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Topical rapamycin as a treatment for fibrofolliculomas in Birt-Hogg-Dubésyndrome: a double-blind placebo-controlled randomized split-face trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30640787" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Laser-Assisted Delivery of Topical Rapamycin: mTOR Inhibition for Birt-Hogg-Dube Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37991821" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Recommendations on scuba diving in Birt-Hogg-Dubésyndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8628872" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Small (&lt;or = 3-cm) renal masses: detection with CT versus US and pathologic correlation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25519458" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Renal cell tumour characteristics in patients with the Birt-Hogg-Dubécancer susceptibility syndrome: a retrospective, multicentre study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22146830" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Renal cancer and pneumothorax risk in Birt-Hogg-Dubésyndrome; an analysis of 115 FLCN mutation carriers from 35 BHD families.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
